Bortezomib plus melphalan and prednisone (VMP regimen) as the initial treatment for IgE multiple myeloma: a case study

被引：8
|
作者：
Sato, Hiroyuki [1 ]
Komiya, Yusuke [1 ]
Hoshino, Shigeru [1 ]
机构：
[1] Saitama Red Cross Hosp, Dept Hematol, Chuo Ku, Saitama 3388553, Japan
来源：
INTERNATIONAL JOURNAL OF HEMATOLOGY | 2014年 / 99卷 / 06期
关键词：
Multiple myeloma; IgE; Bortezomib; VMP regimen; Initial treatment; PLASMA-CELL LEUKEMIA; MAINTENANCE; THALIDOMIDE; EFFICACY; TRIAL; LEVEL; RARE;
D O I：
10.1007/s12185-014-1571-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Patients with IgE multiple myeloma have poor prognosis. Due to the rarity of this condition, no standard treatment has been developed. As the VMP regimen (bortezomib plus melphalan and prednisone) has been reported to be highly effective in the treatment of other types of myeloma, we treated a patient with newly diagnosed IgE myeloma using the VMP regimen. Her myeloma responded well to VMP regimen. The results of this case report thus suggest that physicians may consider VMP regimen for use as the initial treatment for IgE myeloma.
引用
收藏
页码：786 / 789
页数：4
相关论文
共 50 条
  • [21] A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Magarotto, Valeria
    Di Raimondo, Francesco
    Ria, Roberto
    Offidani, Massimo
    Nozzoli, Chiara
    Patriarca, Francesca
    Callea, Vincenzo
    Benevolo, Giulia
    Marasca, Roberto
    Guglielmelli, Tommasina
    Rizzo, Manuela
    Grasso, Mariella
    Petrucci, Maria Teresa
    Omede, Paola
    Gaidano, Gianluca
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 243 - 243
  • [22] Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Cavalli, Maide
    Larocca, Alessandra
    Ria, Roberto
    Offidani, Massimo
    Patriarca, Francesca
    Nozzoli, Chiara
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Callea, Vincenzo
    Baldini, Luca
    Morabito, Fortunato
    Grasso, Mariella
    Leonardi, Giovanna
    Rizzo, Manuela
    Falcone, Antonietta Pia
    Gottardi, Daniela
    Montefusco, Vittorio
    Musto, Pellegrino
    Petrucci, Maria Teresa
    Ciccone, Giovannino
    Boccadoro, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) : 5101 - 5109
  • [23] BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED, PHASE III STUDY
    Palumbo, A.
    Bringhen, S.
    Rossi, D.
    Ria, R.
    Berretta, S.
    Offidani, M.
    Patriarca, F.
    Nozzoli, C.
    Levi, A.
    Guglielmelli, T.
    Benevolo, G.
    Callea, V.
    Liberati, A. M.
    Crippa, C.
    Di Renzo, N.
    Catalano, L.
    De Sabbata, G.
    Rizzi, R.
    Feo, C.
    Mazza, R.
    Farina, G.
    Spadano, A.
    Pisani, F.
    Podda, L.
    Aitoro, G.
    Magarotto, V.
    Astolfi, M.
    Di Raimondo, F.
    Gaidano, G.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 190 - 191
  • [24] Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study
    Fu, Weijun
    Bang, Soo-Mee
    Huang, Honghui
    Kim, Kihyun
    Li, Wei
    An, Gang
    Lee, Je-Jung
    Cai, Zhen
    Jin, Jie
    Wang, Yafei
    Chim, Chor Sang
    Carson, Robin
    Liu, Rui
    Wang, Lingling
    Zhao, Man
    Chen, Xi
    Cui, Canchan
    Hou, Jian
    Wang, Jianxiang
    BLOOD, 2023, 142
  • [25] Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Ria, Roberto
    Offidani, Massimo
    Patriarca, Francesca
    Nozzoli, Chiara
    Levi, Anna
    Guglielmelli, Tommasina
    Benevolo, Giulia
    Callea, Vincenzo
    Olivero, Barbara
    Morabito, Fortunato
    Grasso, Mariella
    Marasca, Roberto
    Rizzo, Manuela
    Falcone, Antonietta Pia
    Gottardi, Daniela
    Montefusco, Vittorio
    Musolino, Caterina
    Zambello, Renato
    Cangialosi, Clotilde
    Pietrantuono, Giuseppe
    Magarotto, Valeria
    Petrucci, Maria Teresa
    Musto, Pellegrino
    Ciccone, Giovannino
    Di Raimondo, Francesco
    Gaidano, Gianluca
    Boccadoro, Mario
    BLOOD, 2009, 114 (22) : 58 - 58
  • [26] MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma.
    San Miguel, J. F.
    Schlag, R.
    Khuageya, N.
    Shpilberg, O.
    Dimopoulos, M.
    Kropff, M.
    Spicka, L.
    Petrucci, M.
    Sarrioilova, O.
    Dmoszynska, A.
    Abdulkadyrov, K.
    Schots, R.
    Jiang, B.
    Palumbo, A.
    Mateos, M.
    Liu, K.
    Cakana, A.
    Van de Velde, H.
    Richardson, P.
    BLOOD, 2007, 110 (11) : 31A - 31A
  • [27] Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma
    Palumbo, Antonio
    Ambrosini, Maria Teresa
    Benevolo, Giulia
    Pregno, Patrizia
    Pescosta, Norbert
    Callea, Vincenzo
    Cangialosi, Clotilde
    Caravita, Tommaso
    Morabito, Fortunato
    Musto, Pellegrino
    Bringhen, Sara
    Falco, Patrizia
    Avonto, Ilaria
    Cavallo, Federica
    Boccadoro, Mario
    BLOOD, 2007, 109 (07) : 2767 - 2772
  • [28] Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients
    Boccadoro, M.
    Bringhen, S.
    Gaidano, G.
    Ria, R.
    Offidani, M.
    Patriarca, F.
    Nozzoli, C.
    Musto, P.
    Petrucci, M.
    Palumbo, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] SUPERIOR EFFICACY WITH BORTEZOMIB PLUS MELPHALAN-PREDNISONE (VMP) VERSUS MELPHALAN-PREDNISONE (MP) ALONE IN PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM): RESULTS OF THE PHASE III MMY-3002 VISTA STUDY
    San-Miguel, J.
    Schlag, R.
    Khuageva, N.
    Dimopoulos, M.
    Shpilberg, O.
    Kropff, M.
    Spicka, I.
    Petrucci, M.
    Palumbo, A.
    Samoilova, O.
    Dmoszynska, A.
    Abdulkadyrov, K.
    Schots, R.
    Jiang, B.
    Mateos, M.
    Anderson, K.
    Esseltine, D.
    Liu, K.
    Cakana, A.
    Van de Velde, H.
    Richardson, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 192 - 193
  • [30] Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
    Palumbo, Antonio
    Bringhen, Sara
    Larocca, Alessandra
    Rossi, Davide
    Di Raimondo, Francesco
    Magarotto, Valeria
    Patriarca, Francesca
    Levi, Anna
    Benevolo, Giulia
    Vincelli, Iolanda Donatella
    Grasso, Mariella
    Franceschini, Luca
    Gottardi, Daniela
    Zambello, Renato
    Montefusco, Vittorio
    Falcone, Antonietta Pia
    Omede, Paola
    Marasca, Roberto
    Morabito, Fortunato
    Mina, Roberto
    Guglielmelli, Tommasina
    Nozzoli, Chiara
    Passera, Roberto
    Gaidano, Gianluca
    Offidani, Massimo
    Ria, Roberto
    Petrucci, Maria Teresa
    Musto, Pellegrino
    Boccadoro, Mario
    Cavo, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (07) : 634 - +
12345